^
Association details:
| Biomarker: | HLA-A*02:01 + MAGEA4 expression |
|---|---|
| Cancer: | Synovial Sarcoma |
| Drug: | afamitresgene autoleucel (ADP-A2M4) (TCR modulator, MAGE-A4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma.
Published date:
05/25/2023
Excerpt:
Pts who were HLA-A*02 positive with advanced synovial sarcoma (with evidence of clinical/radiological progression) positive for MAGE-A4 received afami-cel after lymphodepleting chemotherapy containing fludarabine and cyclophosphamide….96% of pts were typed as HLA-A*02:01P, and median tumor MAGE-A4 expression H-score was 257 (132–300)....Pts with advanced synovial sarcoma treated with afami-cel in SPEARHEAD-1 had encouraging survival, especially those pts with a RECIST response.
DOI:
10.1200/JCO.2023.41.16_suppl.11563
Trial ID:
